Amplia Therapeutics - $INNMF - Ep:057 - Nano Cap Podcast

This week, I speak with Chris Burns, CEO of Amplia Therapeutics, a biotech company developing a promising FAK inhibitor for cancer treatment. Discover the science behind their approach, recent progress in clinical trials, and the vision for transforming pancreatic cancer outcomes.Key Topics:The science behind FAK inhibitors and their role in modulating tumor microenvironmentsHow Amplia's Narmaphonib improves efficacy, durability, and tolerability of pancreatic cancer treatmentsStrategic focus on FDA approval pathway and ongoing clinical trials in the US and AustraliaThe significance of combination therapies in overcoming resistance and enhancing effectivenessThe future potential of FAK inhibitors in treating other solid tumors like ovarian and lung cancerChris Burns' journey from academic research in Australia to biotech leadership and innovationAmplia Therapeutics Website: https://ampliatx.com/Nano Cap Podcast Website https://www.nanocappod.com/DISCLAIMER - The contents of this podcast are for informational purposes only and do not constitute financial, investment, legal, or other professional advice. Listeners should not construe any information discussed as a recommendation to buy, sell, or hold any securities or investments. Always consult with a qualified financial advisor or professional before making any financial decisions.